CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
Peanut powder +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01084174
NCT01084174Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy

Johns Hopkins University·interventional·Posted Mar 10, 2010·Updated Apr 7, 2017

In Brief

A Phase 2 clinical trial evaluating Peanut powder, Peanut extract, and 2 other interventions for Peanut Hypersensitivity and 2 related conditions. Completed, enrolled 21 participants across 1 site.

Detailed Summary

The purpose of this study is to explore the safety and efficacy of a sublingual (under the tongue) immunotherapy (SLIT) dosing regimen and an oral immunotherapy (OIT) regimen in inducing desensitization and long term tolerance in children with persistent peanut allergy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeanut Hypersensitivity, Food Hypersensitivity, Immediate Hypersensitivity
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 10, 2010
Enrollment StartMar 1, 2010
Primary CompletionJan 1, 2012
Study CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.3 years ago

Interventions

Peanut powderdrug

Delivered orally

Peanut extractdrug

Delivered sublingually

Placebo extractdrug

Delivered sublingually

Placebo powderdrug

Delivered orally